Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Samsung Bioepis On The Secrets Of Its Success

Cost Leadership Just One Factor For Korean Biosimilars Specialist

Executive Summary

Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president talks about what is behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.

You may also be interested in...



Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US

Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.

Samsung Biologics Sets Out Growth Plans

Samsung Biologics has set out growth plans – including for its Samsung Bioepis biosimilars venture and its CDMO business – after its sales passed the KRW1trn threshold in 2020.

Samsung Bioepis Partners With Yuhan On Korean Adalimumab

Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel